Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

vTv Therapeutics Q3 EPS $(0.02), Same YoY

vTv Therapeutics (NASDAQ:VTVT) reported quarterly losses of $(0.02) per share. This is unchanged from the same period last year.

byBenzinga Newsdesk

November 9, 2021

1 minute read

vTv Therapeutics (NASDAQ:VTVT) reported quarterly losses of $(0.02) per share. This is unchanged from the same period last year.

Stifel Upgrades Kimco Realty to Buy, Raises Price Target to $27

By Benzinga Newsdesk

Today, 2:56 AM

Stifel analyst Simon Yarmak upgrades Kimco Realty (NYSE:KIM) from Hold to Buy and raises the price target from $25.5 to $27.

KIM

Morgan Stanley Maintains Equal-Weight on Avaya Hldgs, Lowers Price Target to $24

By Benzinga Newsdesk

Today, 2:56 AM

Morgan Stanley analyst Meta Marshall maintains Avaya Hldgs (NYSE:AVYA) with a Equal-Weight and lowers the price target from $26 to $24.

AVYA

Tesla, WD-40 Company And 40 Stocks Moving In Friday’s Mid-Day Session

By Lisa Levin

Today, 2:56 AM

Gainers Aditxt, Inc. (NASDAQ: ADTX) shares surged 75.7% to $0.2812 after the company's Adimune therapeutic program completed a toxicology study indicating a favorable safety profile of ADI-100.

ACER

Needham Maintains Buy on Cogent Biosciences, Lowers Price Target to $23

By Benzinga Newsdesk

Today, 2:56 AM

Needham analyst Ami Fadia maintains Cogent Biosciences (NASDAQ:COGT) with a Buy and lowers the price target from $24 to $23.

COGT

vTv Therapeutics Q3 EPS $(0.02), Same YoY

Related Posts

Stifel Upgrades Kimco Realty to Buy, Raises Price Target to $27

Morgan Stanley Maintains Equal-Weight on Avaya Hldgs, Lowers Price Target to $24

Tesla, WD-40 Company And 40 Stocks Moving In Friday’s Mid-Day Session

Needham Maintains Buy on Cogent Biosciences, Lowers Price Target to $23